Sorafenib Induced Eruptive Melanocytic Lesions
نویسندگان
چکیده
منابع مشابه
Sorafenib induced eruptive melanocytic lesions.
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a pat...
متن کاملDysplastic Nevus with Eruptive Melanocytic Lesions That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia
782 Ann Dermatol Received May 12, 2014, Revised February 16, 2015, Accepted for publication February 25, 2015 Corresponding author: Hyun Jeong Park, Department of Dermatology, Yeouido St. Mary’s Hospital, The Catholic University of Korea, College of Medicine, 10 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea. Tel: 82-2-3779-1230, Fax: 82-2-783-7604, E-mail: [email protected] This is an Open Acc...
متن کاملMelanocytic Lesions in Children
During the last general assembly of our society, held in Miami on February 2010, the election of the new IDS representatives took place. Our president, Peter Soyer, expressed his intention to resign from his role as president and the assembly agreed to give to myself the responsibility to continue his action. Iris Zalaudek was designated to be the new general secretary and Rainer Hofmann-Wellen...
متن کاملDermoscopic criteria and melanocytic lesions.
Dermoscopy is a noninvasive, in vivo method for the early diagnosis of malignant melanoma and the differential diagnosis of pigmented lesions of the skin. By allowing visualization of sub-macroscopic pigmented structures that correlate with specific underlying histopathologic structures, dermoscopy provides a more powerful tool than the naked-eye examination for clinicians to determine the need...
متن کاملVS38 immunostaining in melanocytic lesions.
AIMS To investigate the immunoreactivity of a range of melanocytic lesions, both benign and malignant, with the monoclonal antibody VS38. This was recently described as a marker of reactive/neoplastic plasma cells and, therefore, is useful in the diagnosis of plasmacytoma/myeloma and lymphomas with plasmacytic differentiation. This study was prompted by the recent observation that a plasmacytoi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Dermatology Online Journal
سال: 2013
ISSN: 1087-2108
DOI: 10.5070/d3195018184